A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule.

摘要: 381 Background: Sunitinib is a front-line therapy for metastatic renal cell cancer (mRCC). Recommended dose 50 mg daily; 28 days (d) on/14 d off (traditional schedule; TS). associated with several adverse events (AEs). An ideal treatment modification algorithm not known. We sought to identify (1) common AEs, (2) alternative schedules (AS) that maintained intensity while decreasing and (3) the impact of AS on outcomes. Methods: Single-center retrospective review mRCC pts performed from January 26, 2006 March 1, 2011. Pts > 18 years age who received first-line antiangiogenic sunitinib were eligible. A subset switched at first intolerable AE TS 14 d/7 d, or further adjusted 7 /3 other AS. Control group underwent standard reduction. Pt characteristics including demographics, disease status, laboratory data, AS, outcomes analyzed. Results: 186 eligible identified. At baseline, 87%...